探索基纳素基支架的第6位和第7位导致对RIPK2/3激酶的选择性和强度的变化
Mbilo Misehe1, Marika Matoušová2, Alexandra Dvořáková2
1Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nam. 2, 166 10, Prague 6, Czech Republic; Department of Organic Chemistry, Faculty of Science, Charles University in Prague, Hlavova 2030/8, 128 43, Prague 2, Czech Republic.
European journal of medicinal chemistry
|August 20, 2023
概括
针对受体相互作用蛋白激酶2和3 (RIPK2和RIPK3) 的新型quinazoline衍生物在细胞模型中显示出强大的抑制作用. 这些化合物表现出良好的稳定性和选择性,具有治疗炎症性疾病和癌症的潜力.
科学领域:
- 药用化学 医学化学
- 酶学 是一种酶学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 受体相互作用蛋白激酶2和3 (RIPK2和RIPK3) 是炎症性疾病和癌症的关键标.
- 开发RIPK2和RIPK3的选择性抑制剂对于治疗进步至关重要.
研究的目的:
- 设计和合成针对RIPK2和RIPK3的基于quinazoline的新型衍生物.
- 研究6和7位的修改对抑制活性和选择性的影响.
- 在细胞模型中评估这些衍生物的治疗潜力,并评估它们的药理动力学特性.
主要方法:
- 合成了三系列的金纳林衍生物.
- 对纯化的RIPK1-4.4进行酶分析.
- 基于细胞的测定评估RIPK2-NOD1/2信号通路.
- 在体外代谢稳定性测试 (微体,血).
- 与58个目标外的激酶相对应的激酶选择性分析.
主要成果:
- 强效和选择性RIPK2抑制剂和双RIPK2/3抑制剂的鉴定.
- 在细胞RIPK2-NOD1/2信号通路中证明纳米分子抑制.
- 在人类和小鼠系统中确认了良好的代谢稳定性.
- 在广泛的激酶小组中展示了出色的选择性概况.
结论:
- 在quinazoline衍生物的位置6和7的修改可以微调RIPK2和RIPK3的强度和选择性.
- 开发的化合物代表了开发针对RIPK2/3介导疾病的新疗法的有希望的线索.
- 这些发现为未来用于生物和临床研究的RIPK抑制剂的合理设计提供了宝贵的见解.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
MAPK Signaling Cascades
5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
Assembly of Signaling Complexes
5.8K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
5.8K


